Experimental Laboratory for Children's Bone Metabolism Research, Bone Metabolism Unit, Istituto Auxologico Italiano IRCCS, Milan, Italy.
Adv Exp Med Biol. 2019;1148:201-232. doi: 10.1007/978-981-13-7709-9_10.
Hypophosphatasia (HPP) is a rare genetic disease, characterized by the defective production of tissue-non-specific alkaline phosphatase (TNSALP). Six subtypes of the disease - affecting neonates (beginning in utero), infants, children, or adults - are recognized: perinatal lethal, prenatal benign, infantile, childhood, adult, and odontohypophosphatasia. The clinical presentation of these subtypes is very different and the severity ranges from mild to lethal. This chapter, after an overview of the genetics, epidemiology, classification, and clinical presentation of the different forms of HPP, will review the current experience with enzyme replacement therapy (ERT).
低磷酸酯酶症(HPP)是一种罕见的遗传性疾病,其特征是组织非特异性碱性磷酸酶(TNSALP)的产生缺陷。该疾病有六种亚型,分别影响新生儿(始于宫内)、婴儿、儿童或成人:围产期致死型、产前良性型、婴儿型、儿童型、成人型和牙骨质-低磷酸酯酶症型。这些亚型的临床表现差异很大,严重程度从轻度到致死性不等。本章在概述 HPP 的遗传学、流行病学、分类和临床表现后,将回顾目前酶替代疗法(ERT)的经验。